bioAffinity Technologies, Inc. Common Stock
$9.43
$0.68 (+7.77%)
$9.23Day Range$12.48
Key Statistics
Market Cap
$5.26M
Shares Outstanding
0.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 1, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$10.66
Day High
$12.48
Day Low
$9.23
Volume
10.40M
VWAP
$10.77
Prev Close
$8.75
Transactions
--
Acc. Volume
--
About bioAffinity Technologies, Inc. Common Stock
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCHSIC 873157 employees3300 NACOGDOCHES ROAD, SAN ANTONIO, TX, 78217210-698-5334IPO Sep 1, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001712762
- Composite FIGI
- BBG00H69JDX1
- Share Class FIGI
- BBG00H69JDY0
- Ticker Root
- BIAF
- SIC Code
- 8731
About bioAffinity Technologies, Inc. Common Stock (BIAF) Stock
bioAffinity Technologies, Inc. Common Stock (BIAF) closed the 2026-09-18 session at $9.43, up 7.77% versus the previous close (+0.68). The stock opened at $10.66 and traded between $9.23 and $12.48 during that session. Session trading volume was 10.4M shares. The volume-weighted average price (VWAP) is $10.77.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
bioAffinity Technologies, Inc. Common Stock has a market capitalization of $5.3 million. The company operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry classification. BIAF is listed on the XNAS exchange. The company employs approximately 57 people. bioAffinity Technologies, Inc. Common Stock is headquartered in SAN ANTONIO, TX. The recorded listing date is 2022-09-01.
On this page you can find market BIAF stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector.